Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria

Author(s): Manaf AlMatar*, Osman Albarri*, Essam A. Makky*, Işıl Var and Fatih Köksal

Volume 20, Issue 18, 2020

Page: [1908 - 1916] Pages: 9

DOI: 10.2174/1389557520666200818211405

Price: $65

Abstract

The need for new therapeutics and drug delivery systems has become necessary owing to the public health concern associated with the emergence of multidrug-resistant microorganisms. Among the newly discovered therapeutic agents is cefiderocol, which was discovered by Shionogi Company, Japan as an injectable siderophore cephalosporin. Just like the other β-lactam antibiotics, cefiderocol exhibits antibacterial activity via cell wall synthesis inhibition, especially in Gram negative bacteria (GNB); it binds to the penicillin-binding proteins, but its unique attribute is that it crosses the periplasmic space of bacteria owing to its siderophore-like attribute; it also resists the activity of β-lactamases. Among all the synthesized compounds with the modified C-7 side chain, cefiderocol (3) presented the best and well-balanced activity against multi-drug resistant (MDR) Gram negative bacteria, including those that are resistant to carbapenem. İn this article, an overview of the recent studies on cefiderocol was presented.

Keywords: Cefiderocol, antimicrobial activity, clinical studies, adverse effects, MDR, β-lactam antibiotics, gram negative.

« Previous Next »
Graphical Abstract

[1]
Nordmann, P.; Naas, T.; Poirel, L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis., 2011, 17(10), 1791-1798.
[http://dx.doi.org/10.3201/eid1710.110655] [PMID: 22000347]
[2]
Lamba, M.; Ahammad, S.Z. Sewage treatment effluents in Delhi: A key contributor of β-lactam resistant bacteria and genes to the environment. Chemosphere, 2017, 188, 249-256.
[http://dx.doi.org/10.1016/j.chemosphere.2017.08.133] [PMID: 28886559]
[3]
Daoud, Z.; Farah, J.; Sokhn, E.S.; El Kfoury, K.; Dahdouh, E.; Masri, K.; Afif, C.; Abdel-Massih, R.M.; Matar, G.M. Multidrug-resistant Enterobacteriaceae in Lebanese hospital wastewater: Implication in the one health concept. Microb. Drug Resist., 2018, 24(2), 166-174.
[http://dx.doi.org/10.1089/mdr.2017.0090] [PMID: 28650688]
[4]
Wright, H.; Bonomo, R.A.; Paterson, D.L. New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? Clin. Microbiol. Infect., 2017, 23(10), 704-712.
[http://dx.doi.org/10.1016/j.cmi.2017.09.001] [PMID: 28893690]
[5]
O'Neil, J. Tackling drug resistant infections globally: final report and recommendations., Review on Antimicrobial Resistance, London, England, 2017.
[6]
Giamarellou, H.; Poulakou, G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs, 2009, 69(14), 1879-1901.
[http://dx.doi.org/10.2165/11315690-000000000-00000] [PMID: 19747006]
[7]
Albarri, O.; Var, I.; Köksal, F. Microbial siderophores: potential medicinal applications of the siderophores. J. Biotechnol. Sci. Res., 2020, 6, 32-40.
[8]
Kohira, N.; West, J.; Ito, A.; Ito-Horiyama, T.; Nakamura, R.; Sato, T.; Rittenhouse, S.; Tsuji, M.; Yamano, Y. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob. Agents Chemother., 2015, 60(2), 729-734.
[http://dx.doi.org/10.1128/AAC.01695-15] [PMID: 26574013]
[9]
Portsmouth, S.; Van Veenhuyzen, D.; Echols, R. Machida, M.; Ferreira, J. C. A.; Ariyasu, M.; Nagata, T. D. In Tilte2017; Oxford University Press USS538 ,, 2017.
[10]
Aoki, T.; Yoshizawa, H.; Yamawaki, K.; Yokoo, K.; Sato, J.; Hisakawa, S.; Hasegawa, Y.; Kusano, H.; Sano, M.; Sugimoto, H.; Nishitani, Y.; Sato, T.; Tsuji, M.; Nakamura, R.; Nishikawa, T.; Yamano, Y. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship. Eur. J. Med. Chem., 2018, 155, 847-868.
[http://dx.doi.org/10.1016/j.ejmech.2018.06.014] [PMID: 29960205]
[11]
Iovleva, A.; Doi, Y. Carbapenem-Resistant Enterobacteriaceae. Clin. Lab. Med., 2017, 37(2), 303-315.
[http://dx.doi.org/10.1016/j.cll.2017.01.005] [PMID: 28457352]
[12]
Dunn, G.L. Ceftizoxime and other third-generation cephalosporins: Structure-activity relationships. J. Antimicrob. Chemother., 1982, 10(Suppl. C), 1-10.
[http://dx.doi.org/10.1093/jac/10.suppl_C.1] [PMID: 6295993]
[13]
Neu, H.C. β-Lactam antibiotics: Structural relationships affecting in vitro activity and pharmacologic properties. Rev. Infect. Dis., 1986, 8(Suppl. 3), S237-S259.
[http://dx.doi.org/10.1093/clinids/8.Supplement_3.S237] [PMID: 3529320]
[14]
Ito, A.; Nishikawa, T.; Matsumoto, S.; Yoshizawa, H.; Sato, T.; Nakamura, R.; Tsuji, M.; Yamano, Y. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob. Agents Chemother., 2016, 60, 4384-4386.
[15]
Jean, S-S.; Hsueh, S-C.; Lee, W-S.; Hsueh, P-R. Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria; Taylor & Francis, 2019.
[16]
Ruppé, É.; Woerther, P.L.; Barbier, F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann. Intensive Care, 2015, 5(1), 61.
[http://dx.doi.org/10.1186/s13613-015-0061-0] [PMID: 26261001]
[17]
Zhanel, G.G.; Golden, A.R.; Zelenitsky, S.; Wiebe, K.; Lawrence, C.K.; Adam, H.J.; Idowu, T.; Domalaon, R.; Schweizer, F.; Zhanel, M.A.; Lagacé-Wiens, P.R.S.; Walkty, A.J.; Noreddin, A.; Lynch Iii, J.P.; Karlowsky, J.A. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs, 2019, 79(3), 271-289.
[http://dx.doi.org/10.1007/s40265-019-1055-2] [PMID: 30712199]
[18]
Dobias, J.; Dénervaud-Tendon, V.; Poirel, L.; Nordmann, P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur. J. Clin. Microbiol. Infect. Dis., 2017, 36(12), 2319-2327.
[http://dx.doi.org/10.1007/s10096-017-3063-z] [PMID: 28748397]
[19]
Ito, A.; Nishikawa, T.; Matsumoto, S.; Yoshizawa, H.; Sato, T.; Nakamura, R.; Tsuji, M.; Yamano, Y. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2016, 60(12), 7396-7401.
[PMID: 27736756]
[20]
Ito, A.; Sato, T.; Ota, M.; Takemura, M.; Nishikawa, T.; Toba, S.; Kohira, N.; Miyagawa, S.; Ishibashi, N.; Matsumoto, S.; Nakamura, R.; Tsuji, M.; Yamano, Y. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob. Agents Chemother., 2017, 62(1), e01454-e17.
[http://dx.doi.org/10.1128/AAC.01454-17] [PMID: 29061741]
[21]
Fung-Tomc, J.; Bush, K.; Minassian, B.; Kolek, B.; Flamm, R.; Gradelski, E.; Bonner, D. Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob. Agents Chemother., 1997, 41(5), 1010-1016.
[http://dx.doi.org/10.1128/AAC.41.5.1010] [PMID: 9145861]
[22]
Moynié, L.; Luscher, A.; Rolo, D.; Pletzer, D.; Tortajada, A.; Weingart, H.; Braun, Y.; Page, M.G.; Naismith, J.H.; Köhler, T. Structure and function of the PiuA and PirA siderophore-drug receptors from Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother., 2017, 61(4), e02531-e16.
[http://dx.doi.org/10.1128/AAC.02531-16] [PMID: 28137795]
[23]
Tsai, Y.K.; Fung, C.P.; Lin, J.C.; Chen, J.H.; Chang, F.Y.; Chen, T.L.; Siu, L.K. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob. Agents Chemother., 2011, 55(4), 1485-1493.
[http://dx.doi.org/10.1128/AAC.01275-10] [PMID: 21282452]
[24]
Tsai, Y.K.; Liou, C.H.; Fung, C.P.; Lin, J.C.; Siu, L.K. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. PLoS One, 2013, 8(11)e79640
[http://dx.doi.org/10.1371/journal.pone.0079640] [PMID: 24265784]
[25]
Ito, A.; Nishikawa, T.; Ota, M.; Ito-Horiyama, T.; Ishibashi, N.; Sato, T.; Tsuji, M.; Yamano, Y. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J. Antimicrob. Chemother., 2018, 73(11), 3049-3052.
[http://dx.doi.org/10.1093/jac/dky317] [PMID: 30188999]
[26]
Sato, T.; Yamawaki, K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin. Infect. Dis., 2019, 69(Suppl. 7), S538-S543.
[http://dx.doi.org/10.1093/cid/ciz826] [PMID: 31724047]
[27]
Ito, A.; Nishikawa, T.; Ishii, R.; Kuroiwa, M.; Ishioka, Y.; Kurihara, N.; Sato, T. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies. Open Forum Infect. Dis., 2018, 5, S251-S251.
[http://dx.doi.org/10.1093/ofid/ofy210.703]
[28]
Olofsson, S.K.; Cars, O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect. Dis., 2007, 45(Suppl. 2), S129-S136.
[http://dx.doi.org/10.1086/519256] [PMID: 17683017]
[29]
Kohira, N.; Nakamura, R.; Ito, A.; Nishikawa, T.; Ota, M.; Sato, T. Resistance acquisition studies of cefiderocol by serial passage and in vitro pharmacodynamic model under human simulated exposure., 2018, pp. 6-11.
[30]
Hackel, M.A.; Tsuji, M.; Yamano, Y.; Echols, R.; Karlowsky, J.A.; Sahm, D.F. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob. Agents Chemother., 2017, 61(9), e00093-e00017.
[http://dx.doi.org/10.1128/AAC.00093-17] [PMID: 28630181]
[31]
Tsuji, M.; Kazmierczak, K.; Hackel, M.; Echols, R.; Yamano, Y.; Sahm, D. Cefiderocol (S-649266) susceptibility against globally isolated meropenem non-susceptible Gram-negative bacteria containing serine-and metallo-carbapenemase genes, abstr SUNDAY-25; ASM Microbe, 2017, p. 1.
[32]
Shields, R.K.; Clancy, C.J.; Pasculle, A.W.; Press, E.G.; Haidar, G.; Hao, B.; Chen, L.; Kreiswirth, B.N.; Nguyen, M.H. Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol., 2018, 56(2), e01093-e01017.
[PMID: 29167294]
[33]
Matsumoto, S.; Singley, C.M.; Hoover, J.; Nakamura, R.; Echols, R.; Rittenhouse, S.; Tsuji, M.; Yamano, Y. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob. Agents Chemother., 2017, 61(9), e00700-e00717.
[http://dx.doi.org/10.1128/AAC.00700-17] [PMID: 28630178]
[34]
Tsuji, M.; Singley, C.; Horiyama, T.; Nakamura, R.; Echols, R.; Rittenhouse, S.; Yamano, Y.; Shimada, J. In Tilte; Oxford University Press, 2014.
[35]
Nakamura, R.; Toba, S.; Tsuji, M.; Yamano, Y.; Shimada, J. In Tilte., 2014.
[36]
Ghazi, I.M.; Monogue, M.L.; Tsuji, M.; Nicolau, D.P. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology, 2018, 101(5-6), 278-284.
[http://dx.doi.org/10.1159/000487441] [PMID: 29471305]
[37]
Saisho, Y.; Katsube, T.; White, S.; Fukase, H.; Shimada, J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob. Agents Chemother., 2018, 62(3), e02163-e02117.
[http://dx.doi.org/10.1128/AAC.02163-17] [PMID: 29311072]
[38]
Katsube, T.; Wajima, T.; Ishibashi, T.; Arjona Ferreira, J.C.; Echols, R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob. Agents Chemother., 2016, 61(1), e01381-e01316.
[PMID: 27795374]
[39]
Matsunaga, Y.; Echols, R.; Katsube, T.; Yamano, Y.; Ariyasu, M.; Nagata, T. Cefiderocol (S-649266) for nosocomial pneumonia caused by Gram-negative pathogens: study design of APEKS-NP, a phase 3 double-blind parallel-group randomized clinical trial. B42. Critical Care: The Fever-Infections in the ICU; American Thoracic Society, 2018, pp. A3290-A3290.
[40]
Portsmouth, S.; Vennhuyzen, D.; Echols, R.; Machida, M.; Ferrreira, J. In Tilte., 2017.
[41]
Katsube, T.; Echols, R.; Arjona Ferreira, J.C.; Krenz, H.K.; Berg, J.K.; Galloway, C. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment. J. Clin. Pharmacol., 2017, 57(5), 584-591.
[http://dx.doi.org/10.1002/jcph.841] [PMID: 27874971]
[42]
Portsmouth, S.; van Veenhuyzen, D.; Echols, R.; Machida, M.; Ferreira, J.C.A.; Ariyasu, M.; Tenke, P.; Nagata, T.D. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect. Dis., 2018, 18(12), 1319-1328.
[http://dx.doi.org/10.1016/S1473-3099(18)30554-1] [PMID: 30509675]

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy